LOS ANGELES, May 11: The world’s biggest drug makers have for years enjoyed rich premiums for their medicines in the US market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown dependent on higher US prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe’s government-run health plans clamp down on spending and sales growth in emerging markets stutters. (agencies)
^^^^
Trending Now
E-Paper
Follow our WhatsApp channel